Clinical Trial Update: Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of BNT141 in CLDN18.2-positive gastric, pancreatic, ovarian, and biliary tract cancers. The study was terminated and results were posted, focusi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma
• Esophageal Adenocarcinoma
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma
• Ovarian Cancer
• Pancreatic Cancer

Drugs mentioned

• BNT141

Snippet

Sponsor: BioNTech SE | Conditions: Solid Tumor, Gastric Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-10-02